| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2474550 | Acta Pharmaceutica Sinica B | 2013 | 5 Pages |
The sodium/glucose cotransporter 2 (SGLT2) is responsible for the majority of glucose reabsorption in the kidney, and currently, SGLT2 inhibitors are considered as promising hypoglycemic agents for the treatment of type 2 diabetes mellitus. By constructing CHO cell lines that stably express the human SGLT2 transmembrane protein, along with a fluorescent glucose transporter assay that uses 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]2-deoxyglucose (2-NBDG) as a glucose analog, we have developed a nonradioactive, cell-based assay for the discovery and characterization of SGLT2 inhibitors.
Graphical abstractA nonradioactive, cell-based assay for the discovery and characterization of SGLT2 inhibitors was developed using 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]2-deoxyglucose (2-NBDG) as a glucose analog.Figure optionsDownload full-size imageDownload as PowerPoint slide
